Agilent Q3 FY26: Cleaner Growth and Margin Recovery Signal Thesis Inflection

What happened

Agilent reported third-quarter fiscal 2026 revenue of $1.88 billion, up 8.1% reported and 7.3% core, beating prior growth trajectories and confirming gradual demand recovery. GAAP net income rose to $362 million ($1.28 per share) from $336 million ($1.18 per share) a year ago, and non-GAAP net income reached $459 million, indicating operating leverage is finally returning after several quarters of margin pressure. The results land two quarters after the DeepValue WAIT call, which had flagged margin compression and execution noise in Q1 FY26; this print suggests those headwinds are easing, though the company did not disclose granular margin or segment details in the initial release. Importantly, the quarter likely benefited from fewer tariff impacts and better mix, but the press release omits specifics on China and academic end markets, which were key risks in the prior thesis. Overall, the Q3 results provide the first clean evidence that Agilent's order book conversion and pricing actions are translating into improved profitability, reducing the likelihood of the bear case.

Implication

Investors should recognize that Q3 FY26 delivered both revenue growth and EPS expansion, which directly addresses the primary concern from the prior assessment that growth was not converting to earnings quality. The reported GAAP EPS of $1.28 versus $1.18 is a meaningful step up, and non-GAAP net income of $459 million implies operating margin recovery toward the base-case 21–22% range. However, the absence of detailed margin decomposition and segment commentary in this release warrants caution; management may be selectively framing results, and sustained improvement must be verified in the 10-Q filing. The stock was priced at a WAIT level near $113 with limited margin of safety, so a positive reaction may already discount some of the improvement, and buying here requires confidence that China and academic headwinds are truly abating. A prudent approach is to wait for the next earnings call and 10-Q to confirm that the margin expansion is driven by operational efficiency rather than one-time gains, but incremental positions could be initiated on pullbacks to the $120–125 range if the recovery thesis holds.

Thesis delta

The original WAIT thesis was based on revenue growth without earnings quality and a lack of clean conversion. Q3 FY26 begins to close that gap by showing GAAP EPS growth of 8.5% year-over-year alongside 8.1% reported revenue growth, which implies margin re-expansion. This shifts the thesis from 'show me' to 'early evidence of inflection,' but full confirmation requires the 10-Q to validate that margins improved on a like-for-like basis and that book-to-bill remains ≥1.